Yesterday
Lean profits, leaner CEO: Inside the Novo Nordisk miracle
The global chief executive of weight loss drug giant Novo Nordisk, Mike Doustdar, lost 25 kilos – but he did it the old-fashioned way.
This Month
Sunscreen regulation faces overhaul after SPF failures
The Therapeutic Goods Administration is moving to restore public trust after an investigation found many products failed to meet their label claims.
People are dumping their top-tier health insurance
The exodus is expected to accelerate when average premiums increase by 4.4 per cent from April 1, the largest annual hike in almost a decade.
Biotech HaemaLogiX prepares for ASX debut; taps Ord Minnett, Canaccord
When equity markets are settled, Ord Minnett and Canaccord Genuity are ready to pull the trigger and will probably sound for a $20 million to $25 million capital raising.
Bain flaunts Estia 2.0 as IPO roadshow gets under way
Same business, same CEO, what’s changed in two years that Estia’s gone from being the ASX’s dog, sold for $838 million, to a business estimated to be worth $3 billion odd?
NDIS providers increasing fees without improving service: analysis
The National Disability Insurance Scheme pricing model encourages providers to bump up their fees without increasing services, an analysis shows.
Olympian turned doctor takes the plunge in $1.4b ice bath market
Matt Guest has brought in former Australian cricket captain Tim Paine and is raising $2 million to make an easy-to-use backyard ice plunge a reality.
I’m a longevity doctor. Here’s why I’ll never give up alcohol
I don’t drink regularly or a lot, though I make an exception at Oktoberfest, when I enjoy drinking beer by the litre. Because life is too short not to have fun.
Healthscope’s La Spina ousted after bust-up with receivers
The former Qantas executive has been removed as CEO of the failed hospitals operator, despite insisting he remains in the role.
Poo patrol and sensory gardens: The NDIS can pay for that
Sex, drugs and alcohol are banned from the NDIS, but many other items including skiing, kayaking and surfing are still in a grey zone.
Regal-backed Immutep dives 90pc after it abandons cancer drug trial
More than $500 million was wiped from the company’s market capitalisation in a blow to major investors including the Phil King-run fund management giant.
Healthscope shrinks in size as Adelaide hospitals exit the group
Australia’s second-biggest private hospital group lost three Adelaide hospitals from its network, although it said this would not impact its not-for-profit plan.
CEOs and celebrities swear by this 30:30:30 nutrition rule
It’s not enough to just concentrate on protein and vegetables. A British nutritionist has come up with a specific formula.
CDC boss says data, public trust must improve to handle next pandemic
The boss of the new Australian Centre for Disease Control says mistakes are inevitable in pandemics, but COVID-19 was handled better here than in other countries.
Melbourne duo backed by rich investors in the quest for eternal youth
Two Melbourne entrepreneurs have raised money from members of the Myer family, with their biotech now valued at $90 million.
Eli Lilly confirms oral GLP-1 weight-loss drug being evaluated by TGA
The expected launch of a second oral GLP-1 in the United States has sparked major interest in Australia.
Monash IVF settles lawsuit with families linked to embryo mix-ups
The fertility company had told investors insurance would cover settlements after a mix-up resulted in a patient giving birth to someone else’s baby.
BGH Capital woos co-investors for $2.4b pharmaceutical bet
The moves comes after BGH quietly announced the acquisition of Aspen Pharmacare’s Asia Pacific business in the final days of 2025.
February
‘More regulation to pull a beer’: NDIS providers under fire
The sheer volume of unregistered NDIS providers who do not have to comply to specific standards has raised further integrity and sustainability concerns.
Weight-loss drugs drive double-digit Chemist Warehouse sales
The popularity of the medication is boosting sales in hair and beauty products at the pharmacies giant, and a new oral version will drive demand even higher.
Ramsay earnings rise points to hospital giant’s turnaround
Investors in the country’s largest private health group were buoyed by the result, which they said showed chief executive Natalie Davis’ strategy was working.
Why a $10b autism bill is forcing a rethink of the NDIS
The number of older children and adults being diagnosed with it under the National Disability Insurance Scheme is surging, costing taxpayers far more each year.
Blackbird reveals the eye-popping returns from its big Eucalyptus bet
The Australian telehealth unicorn announced its $1.6 billion sale to New York-listed Hims & Hers last year, minting a string of immediate millionaires.
IFM Investors’ $400m Benson Radiology acquisition hits the wall
It’s back to the drawing board for Benson Radiology’s 55 doctor-shareholders who had been hoping to pocket a nice cheque in time for Christmas.
